tbuckley/cabot-search huggingface dataset:
THE ST. LOUIS MEETING
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Paralytic Poliomyelitis—United States, 1980-1994
Journal: JAMA (1997)

The Advisory Committee on Immunization Practices (ACIP) recently recommended a sequential vaccination schedule of two doses of inactivated poliovirus vaccine (IPV) followed by two doses of oral poliovirus vaccine (OPV) for routine vaccination of children in the United States (1). ACIP revised its recommendation for routine poliovirus vaccination for three reasons: 1) paralytic poliomyelitis attributable to indigenously acquired wild poliovirus has not occurred in the United States since 1979 (2), 2) progress toward global eradication of poliomyelitis has reduced the risk for importation of wild poliovirus into the United States (3), and 3) vaccine-associated paralytic poliomyelitis (VAPP) continues to occur. ACIP has recommended that implementation of this new vaccination schedule begin in early 1997. This report summarizes both the epidemiology of paralytic poliomyelitis in the United States reported during 1980-1994 and provisional reports for 1995-1996 and updates the estimated risk for VAPP. These findings indicate that the overall estimated risk for VAPP has remained constant.
Leads from the MMWR. Plague--South Carolina
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Botulism: Type E—A Report of Eight Simultaneous Cases.
Authors: Richard L. Whittaker
Journal: Annals of Internal Medicine (1964)

s1 April 1964Botulism: Type E—A Report of Eight Simultaneous Cases.Richard L. Whittaker, M.D., F.A.C.P., Robert B. Gilbertson, M.D., F.A.C.P., Albert S. Garrett Jr., M.D.Richard L. Whittaker, M.D., F.A.C.P.Search for more papers by this author, Robert B. Gilbertson, M.D., F.A.C.P.Search for more papers by this author, Albert S. Garrett Jr., M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-60-4-731_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn October 1963, nine cases of botulism were seen in a moderate sized metropolitan area of East Tennessee. Seven appeared within a 24-hr period. Two appeared 5 days later. Epidemiologic investigation showed the source of toxin to be smoked whitefish prepared by a Michigan packer and distributed by a large supermarket chain. Bacteriologic and toxicologic studies identified the toxin as type E, that type associated with fish contamination.Since all cases were managed at one hospital by a "team" of physicians, we have been able to analyze various aspects of the problem critically. We feel that certain clinical facts and... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Richard L. Whittaker, M.D., F.A.C.P.; Robert B. Gilbertson, M.D., F.A.C.P.; Albert S. GarrettJr., M.D.Affiliations: Knoxville, Tennessee PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1964Volume 60, Issue 4Page: 731-731KeywordsBotulismEpidemiologyToxins ePublished: 1 December 2008 Issue Published: 1 April 1964 PDF downloadLoading ...
BATHING AS A SOCIAL AMUSEMENT
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Legal and medical bases for granting asylum in the USA to women with female genital mutilation: a systematic review
Authors: Sara Gorman
Journal: The Lancet Global Health (2013)

BackgroundA precedent exists for granting asylum based on fear of persecution in the form of female genital mutilation (FGM), but it does not apply to women who have already undergone FGM on the logic that they have no grounds to fear further persecution. I assessed the published work about whether women who have already undergone FGM should be granted asylum to the USA on the basis of the medical consequences of the procedure.MethodsI searched legal and medical databases (HeinOnline and PubMed) for the terms: “asylum and female genital mutilation”, “health consequences of female genital mutilation”, “mental health consequences of female genital mutilation”, and “PTSD and female genital mutilation”. All articles published since 1994 were screened. In the legal database, only documents fitting the description “articles”, rather than “notes” or “commentaries”, were screened. I excluded: articles about asylum or FGM but not about both, articles that did not discuss asylum for women who have already undergone FGM, articles that relayed anecdotes about treatment or clinical advice for patients who have undergone FGM, articles about countries other than the USA, and articles analysing women's and health-care providers’ attitudes toward FGM. Articles had to be about FGM in particular and not about other forms of violence against women.FindingsThe database searches yielded 1007 articles. Most articles (n=881) were from the legal database. The final analysis included 35 articles. The medical—especially obstetric—complications associated with FGM can be severe but might be reduced by deinfibulation, which is done in the USA. Women who are forced to return to their native countries might be subject to a repeat FGM procedure. Furthermore, return to the scene of FGM engenders substantial risk of worsening trauma-related psychiatric illness.InterpretationWomen who have already undergone FGM should have the right to be granted asylum in the USA on the basis of significant threats to their physical and mental health if returned to their native countries.FundingNone.
THE INTERN SHORTAGE
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oral surgery in patients with atherosclerotic heart disease. Benign effect of epinephrine in local anesthesia
Authors: G. D. Elliott
Journal: JAMA (1974)

Forty patients with documented atherosclerotic heart disease were examined by electrocardiography and determination of blood pressures and pulse rates 24 hours before oral surgery, immediately preoperatively, and during surgery at intervals of one, five, and ten minutes after injections of 2% lidocaine hydrochloride with and without 1:50,000 epinephrine. No significant changes occurred in the electrocardiograms, blood pressures, or heart rates during the study. We found no reason to withhold epinephrine from local anesthetics administered to patients with atherosclerotic heart disease.
Physiologic Changes Before and After Radiation Treatment for Carcinoma of the Lung
Authors: Patricia A. German
Journal: JAMA (1968)

Physiologic data concerning 30 patients with bronchogenic carcinoma were obtained before radiation therapy and at intervals thereafter. At pretreatment examination, abnormalities were found in all patients. Postirradiation data revealed decreased residual volumes and diffusing capacities with little progression of airway obstruction. No parameter evaluated demonstrated correlation with the volume dose of the tissue irradiated. Pretreatment lung scintiscans disclosed areas of decreased capillary blood flow which were greater at times than would be suggested by chest roentgenograms. Postirradiation lung scans showed further decreases in the pulmonary capillary blood flow in areas initially affected. It is suggested that alterations in the capillary blood flow and resultant tissue changes were initiated by tumor and aggravated by radiation therapy. The data do not confirm other reports attributing the development of severe pulmonary disability to radiation therapy of the lung.
Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites
Authors: P Angeli
Journal: Hepatology (1994)

Although some clinical studies seem to prove the efficacy of nonantialdosteronic potassium-sparing diuretics in the treatment of ascites, no controlled study has compared the efficacy of these drugs with that of antialdosteronic diuretics. Forty nonazotemic cirrhotic patients were randomized to receive amiloride (group A, n = 20) or potassium canrenoate (group B, n = 20). The initial doses of amiloride and potassium canrenoate were 20 mg and 150 mg, respectively. The doses were increased in stepwise fashion to 60 and 500 mg/day, respectively, if no response ensued. Nonresponders to the highest doses of each drug were later treated with potassium canrenoate and amiloride, respectively. Seven of 20 group A patients responded to amiloride, whereas 14 of 20 group B patients responded to potassium canrenoate (p < 0.025). Seven of 13 non-responders to amiloride later responded to potassium canrenoate, whereas only two of the nonresponders to potassium canrenoate later responded to amiloride. The diuretic responses to amiloride and potassium canrenoate were related to the activity of the reninaldosterone system. All responders to amiloride (n = 9) had normal values of plasma aldosterone. All nonresponders to amiloride who later responded to potassium canrenoate (n = 7) had increased levels of plasma aldosterone. Moreover, on comparison of all responders (n = 21) and nonresponders (n = 12) to potassium canrenoate, a higher degree of renal proximal sodium reabsorption (with consequent limitation of sodium delivery to the distal tubule) was found to be the main difference. These results indicate that (a) amiloride is less effective than potassium canrenoate in the treatment of ascites in cirrhotic patients and (b) amiloride may represent an alternative to potassium canrenoate only in patients without increased activity of the renin-aldosterone system. (Hepatology 1994;19:72–79).
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Authors: Glynn Dennis, Brad T Sherman, Douglas A Hosack, Jun Yang, Wei Gao, H Clifford Lane, Richard A Lempicki
Journal: Genome biology (2003)

The distributed nature of biological knowledge poses a major challenge to the interpretation of genome-scale datasets, including those derived from microarray and proteomic studies. This report describes DAVID, a web-accessible program that integrates functional genomic annotations with intuitive graphical summaries. Lists of gene or protein identifiers are rapidly annotated and summarized according to shared categorical data for Gene Ontology, protein domain, and biochemical pathway membership. DAVID assists in the interpretation of genome-scale datasets by facilitating the transition from data collection to biological meaning.
Fatal Asthma
Authors: Leslie C. Grammer
Journal: Annals of Internal Medicine (1998)

Medical Writings1 October 1998Fatal AsthmaLeslie C. Grammer, MDLeslie C. Grammer, MDNorthwestern University Medical School, Chicago, IllinoisSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-7-199810010-00028 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Fatal Asthma; Sheffer AL; ed. 607 pages. New York: Marcel Dekker; 1998. $195.00. ISBN 0824701550. Order phone 800-228-1160.Field of medicine: Internal medicine and pulmonary disease.Format: Hardcover book.Audience: Internists, pediatricians, pulmonologists, and allergist-immunologists.Purpose: To define the factors that contribute to death due to asthma and to provide ways for clinicians to prevent fatal outcomes with appropriate therapy.Content: This compendium of 34 review articles summarizes various aspects of fatal asthma, including epidemiology, pathophysiology, natural history, socioeconomic risk factors, respiratory infections, atmospheric pollution, the use of β2 agonists, patient compliance, and recommendations for assessment and treatment.Highlights: The ... Author, Article, and Disclosure InformationAffiliations: Northwestern University Medical School, Chicago, Illinois PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1998Volume 129, Issue 7Page: 595KeywordsAsthmaEpidemiologyMedical risk factorsPollutionPulmonary diseasesRespiratory system proceduresRhinitisUpper respiratory tract infections ePublished: 15 August 2000 Issue Published: 1 October 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
PIPERAZINE IN GOUT.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prospective evaluation of prescribing preferences (PPrefs) of U.S.-based oncologists in the postdocetaxel mCRPC patient (Pt).
Authors: Charles J. Ryan, Arden Buettner, Susan L. Britton, Maria Lankford, Doug B. Neely, Mark R. Green
Journal: Journal of Clinical Oncology (2014)

e16011 Background: In 2013 we studied PPrefs of 194 US-based medical oncologists (MOs) for pts. with mCRPC progressing during/after docetaxel-prednisone (DP) therapy (Rx). A validated, proprietary, live, case-based market research tool was utilized with a core case scenario and 4 distinct outcomes after initiation of DP therapy. Data acquired using blinded audience response technology. Research support sources were double blinded. Methods: Core case - 59 y/o with rad prostatectomy → PSA failure at 15 months (MOS) → pelvic RT; 16 MOS post RT → rise in PSA and 3.5 cm pelvic node. Over the next 42 MOS multiple systemic Rxs were used including CAB, anti-androgen withdrawal, sipuleucel-t, and abiraterone-prednisone (AP). Now the pt has PSA progression, increasing bone disease with bone pain (BP) →initiation of DP. PPrefs for 4 outcomes of DP Rx probed: 1. DP 75 mg/m2 Q 3 wk. x 6 cycles (cy) → BP elimination/PSA response → stop DP due to cumulative myelosuppression/progressive fatigue. Pt is more active off CT with PS 1. 3 MOS later→ asymptomatic 30% rise in PSA. 2. 4 cy of DP →decrease in PSA, BP, node size. Prior to cy 6 has asymptomatic PSA progression. 3. 4 cy of DP → decrease in PSA, BP, node size. Prior to cy 6, has both PSA rise and BP progression. 4. 2 cy of DP → progression with increased BP, PSA, and pelvic nodal disease. Results: (See Table.) Conclusions: Next PPrefs after DP were scenario dependent. With no recurrent/progressive BP, ENZ is most common PPref, even in this AP refractory pt. PPref for 2nd line CT increases with more rapid, symptomatic disease progression. Emerging PPrefs for 223RaCl2 in scenarios 3 and 4 are notable. Data on additional PPref assessments from early 2014 will be available by ASCO 2014. Tx options Scenario 1 2 3 4 5/11/13 10/5/13 5/11/13 10/5/13 5/11/13 10/5/13 5/11/13 10/5/13 N=89 N=104 N=90 N=100 N=88 N=99 N=88 N=88 Surveillance 34% 40% N/O N/O N/O N/O N/O N/O AP N/O N/O 14% 20% 7% 8% 3% 5% *Alpharadin/223 RaCl2 1% 0 2% 5% 5% 54% 5% 36% Cabazitaxel-P 12% 13% 30% 20% 42% 13% 55% 32% Enzalutamide (ENZ) 25% 28% 33% 28% 30% 10% 20% 11% ENZ-P 16% 13% 9% 17% 9% 10% 7% 1% Mitoxantrone-P 0 1% 2% 0 2% 1% 3% 1% Other 12% 5% 10% 10% 5% 4% 7% 14% Abbreviations: N/O, not offered. *Offered as “Alpharadin for single pt use” on 5/11/13.
JAMA Pediatrics
Authors: Phil Fontanarosa, Annette Flanagin, Paula Glitman, Brenda Gregoline, Tracy Frey, Shannon Sparenga, Miriam Cintron, Paul Ruich, Diane Cannon, Vickey Golden, Connie Manno, Laura Copyreaders, Catherine Adamcyzk, Jan Alden, Mary Clavey, Cheryl Coerver-Connolly, Gillian Davidow, Laura Dickens, Juliann King, Donna Tarsney, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Managers, Staff Gardner- Gullens, Helene Biernacki, Fanny Brown, Paul Frank, Rachell Lozano, Michaela Mark, J Neff, Kate Pezalla, Gale Saulsberry, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Christopher Hastings, Craig Mccaffrey, Reuben Rios, Ronna Henry, Staff Bird, Alison Burke, Cassio Lynm, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Jann Ingmire, Deanna Bellandi, Jim Periodical, Thomas Staff, Monica Smith, Jeffery Bonistalli Manager, Kathy Staff, Mirna Monal, Tim Melroy, Thalia Moss, Tem Harrier, Susan Henning, Mark Thornbury, Tricia Castellano, Saskia Bolore, Gretchen Linder, Brian Mccartney, Rebecca Haas, Christine Hearne, Irma Lara, Audra Lawlor, Scott Marketing, Matt Herron, Elizabeth Solaro, Geoffrey Flick Managers, Rick Bell, Paul Gee, Michael Mcgraw, Sara Nagy, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Sue Sherrill, Brian Shields Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Diane Darnell, Colleen Kelly, Chris Meyer, Emily Mitchell, Jaye Mize, Sean O'donnell, Sean Ohlson, Phil O'leary, Ryan Patella, Susan Price, Denise Steinhauser, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Susan Chiara, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Noemi Rivera, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Brenda Chandler-Grayer, Scott Curl, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Fred Marshall, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, James Madara, Bernard Hengesbaugh, Dimitri Christakis, Washington Joffe, Ron Keren, Suzanne Shuey, Benjamin French, Peter Cummings, Samir Shah, Howard Bauchner, Frederick Rivara, Matthew Davis, Ann Arbor, Cherrie Boyer, San Francisco, Robert Bradley, Maria Britto, John Campo, Aaron Carroll, Indiana Frank, Joseph Chaloupka, Mitchell Cohen, Chris Feudtner, Kathleen Janz, Iowa City, Terry Klassen, Joyce Lee, Michigan Michelle, Huckaby Lewis, Maryland Saiman, New York, York Samir, Martha Sola-Visner, Jean-Claude Carel, Shabir Madhi, Ben Marais, Frank Oberklaid, Susan Sawyer, Joan-Carles Surís
Journal: JAMA Pediatrics (2013)

Vision JAMA Pediatrics will be the most respected source of information for investigators, providers, and policy makers seeking the highest quality evidence to guide decision-making.